Patents by Inventor Chao-Yie Yang

Chao-Yie Yang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Macrocyclic indoles as Mcl-1 inhibitors
    Patent number: 11691989
    Abstract: Disclosed is compound of formula I and the pharmaceutically acceptable salts and solvates thereof, wherein R, R1a, R1b, R1h, L2, L3, #, #, # are as defined as set forth in the re) specification. Disclosed is compound of formula I for use to treat a condition or disorder responsive to Mcl-1 inhibition such as cancer.
    Type: Grant
    Filed: November 20, 2019
    Date of Patent: July 4, 2023
    Assignees: ASCENTAGE PHARMA (SUZHOU) CO., LTD., THE REGENTS OF THE UNIVERSITY OF MICHIGAN, ASCENTAGE PHARMA GROUP CORP LIMITED
    Inventors: Hao Chen, Wenming Chen, Chao Li, Dongbo Li, Yu Jing, Guozhi Tang, Yunlong Zhou, Shaomeng Wang, Chao-Yie Yang
  • SMALL MOLECULE STAT PROTEIN DEGRADERS
    Publication number: 20230159573
    Abstract: The present disclosure provides compounds represented by Formula (I) and the pharmaceutically acceptable salts and solvates thereof, wherein R1a, R1b, R3a, R4, A, E1, E2, M, and Q are as set forth in the specification. Compounds of Formula (I) are STAT protein degraders and thus are useful for the treatment of cancer and other diseases.
    Type: Application
    Filed: March 26, 2021
    Publication date: May 25, 2023
    Inventors: Shaomeng Wang, Haibin Zhou, Renqi Xu, Longchuan Bai, Donna McEachern, Jeanne Stuckey, Chao-Yie Yang
  • SMALL MOLECULE DEGRADERS OF STAT3
    Publication number: 20230083015
    Abstract: The present disclosure provides compounds represented by Formula I or Formula VIII: wherein R1a, R1b, M, A, E, QA, and QB are as defined in the specification, and the salts and solvates thereof. Compounds of Formula I are degraders of STAT3 or degraders of STAT3 and STAT1. Compounds of Formula VIII are inhibitors of STAT3. STAT3 degraders and inhibitors are useful for the treatment of cancer and other diseases.
    Type: Application
    Filed: March 26, 2020
    Publication date: March 16, 2023
    Inventors: Shaomeng Wang, Haibin Zhou, Renqi Xu, Longchuan Bai, Donna McEachern, Jeanne Stuckey, Chao-Yie Yang
  • Fused 1,4-oxazepines and related analogs as BET bromodomain inhibitors
    Patent number: 11548899
    Abstract: The present disclosure provides fused 1,4-oxazepines and related analogs represented by Formula (I) and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R1, R2a, R2b, R3a, R3b, R4, R5, A, and Y are as defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula (I) to treat a condition or disorder responsive to inhibition of BET bromodomains such as cancer.
    Type: Grant
    Filed: February 15, 2017
    Date of Patent: January 10, 2023
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Shaomeng Wang, Bing Zhou, Yang Hu, Chao-Yie Yang, Chong Qin
  • MACROCYCLIC FUSED PYRRAZOLES AS MCL-1 INHIBITORS
    Publication number: 20220396587
    Abstract: Provided are compounds represented by Formula IA: (IA), and the pharmaceutically acceptable salts and solvates thereof, wherein R, R1a, R1b, L1, L2, L3, X, A, B and C are as defined as set forth in the specification. Also provided compounds of Formula IA for use to treat a condition or disorder responsive to Mcl-1 inhibition such as cancer.
    Type: Application
    Filed: January 22, 2020
    Publication date: December 15, 2022
    Inventors: Guozhi Tang, Dongbo Li, Liugen Li, Xianchan Zha, Wenming Chen, Shaomeng Wang, Chao-Yie Yang
  • SPIROCYCLIC ANDROGEN RECEPTOR PROTEIN DEGRADERS
    Publication number: 20220380368
    Abstract: The present disclosure provides compounds represented by Formula (I) and the salts or solvates thereof, wherein R3a, E, L, A1, B1, X1, X2, Z1, and Z2 are as defined in the specification. Compounds having Formula (I) are androgen receptor degraders useful for the treatment of cancer and other diseases.
    Type: Application
    Filed: September 18, 2020
    Publication date: December 1, 2022
    Inventors: Shaomeng Wang, Xin Han, Weiguo Xiang, Bukeyan Miao, Chong Qin, Lijie Zhao, Jianfeng Lu, Tianfeng Xu, Chao-Yie Yang
  • Macrocyclic spiroethers as Mcl-1 inhibitors
    Patent number: 11498928
    Abstract: Provided are compounds represented by Formula (I-A) and the pharmaceutically acceptable salts and solvates thereof, wherein R8, R9a, R9b, R9c, R9d, X, Y, Z, Z1, W, and (aa) are as defined as set forth in the specification. Provided are also compounds of Formula (I-A) for use to treat a condition or disorder responsive to Mcl-1 inhibition such as cancer.
    Type: Grant
    Filed: January 17, 2020
    Date of Patent: November 15, 2022
    Assignees: ASCENTAGE PHARMA (SUZHOU) CO., LTD., THE REGENTS OF THE UNIVERSITY OF MICHIGAN, ASCENTAGE PHARMA GROUP CORP LIMITED
    Inventors: Jianyong Chen, Yunlong Zhou, Guozhi Tang, Chengzhe Wu, Leilei Zhao, Lingling Jiao, Binghua Sheng, Shaomeng Wang, Chao-Yie Yang, Hao Chen, Wenliang Hu, Yu Jing
  • MACROCYCLIC INDOLES AS MCL-1 INHIBITORS
    Publication number: 20220340595
    Abstract: Disclosed is compound of formula I and the pharmaceutically acceptable salts and solvates thereof, wherein R, R1a, R1b, R1h, L2, L3, #, #, # are as defined as set forth in the re) specification. Disclosed is compound of formula I for use to treat a condition or disorder responsive to Mcl-1 inhibition such as cancer.
    Type: Application
    Filed: November 20, 2019
    Publication date: October 27, 2022
    Inventors: Hao Chen, Wenming Chen, Chao Li, Dongbo Li, Yu Jing, Guozhi Tang, Yunlong Zhou, Shaomeng Wang, Chao-Yie Yang
  • IMIDAZOPYRIMIDINES AS EED INHIBITORS AND THE USE THEREOF
    Publication number: 20220227778
    Abstract: The present disclosure provides compounds represented by Formula I: wherein R1, R2, R3, and R4 are as defined in the specification, and the salts and solvates thereof. Compounds of Formula I are EED inhibitors. EED inhibitors are useful for the treatment of cancer and other diseases.
    Type: Application
    Filed: July 16, 2020
    Publication date: July 21, 2022
    Inventors: Shaomeng Wang, Rohan Rej, Changwei Wang, Mi Wang, Jianfeng Lu, Chao-Yie Yang, Ester Fernandez-Salas, Jeanne Stuckey
  • ANDROGEN RECEPTOR PROTEIN DEGRADERS
    Publication number: 20220081435
    Abstract: The present disclosure provides compounds represented by Formula (I): A-L-B (I), and the salts or solvates thereof, wherein A, L, and B are as defined in the specification. Compounds having Formula (I) are androgen receptor degraders useful for the treatment of cancer.
    Type: Application
    Filed: December 19, 2019
    Publication date: March 17, 2022
    Inventors: Shaomeng Wang, Xin Han, Chao Wang, Chong Qin, Weiguo Xiang, Tianfeng Xu, Chao-Yie Yang
  • Pyrrolo[2,3-C]pyridines and related analogs as LSD-1 inhibitors
    Patent number: 11168082
    Abstract: The present disclosure provides compounds represented by Formula I and II: and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3, X, W, Y, and Z are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I and II for use to treat a condition or disorder responsive to LSD1 inhibition such as cancer.
    Type: Grant
    Filed: May 15, 2018
    Date of Patent: November 9, 2021
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Shaomeng Wang, Dengyou Zhang, Canhui Zheng, Zhuo Chen, Liu Liu, Liyue Huang, Chao-Yie Yang
  • MACROCYCLIC SPIROETHERS AS MCL-1 INHIBITORS
    Publication number: 20210340158
    Abstract: Provided are compounds represented by Formula (I-A) and the pharmaceutically acceptable salts and solvates thereof, wherein R8, R9a, R9b, R9c, R9d, X, Y, Z, Z1, W, and (aa) are as defined as set forth in the specification. Provided are also compounds of Formula (I-A) for use to treat a condition or disorder responsive to Mcl-1 inhibition such as cancer.
    Type: Application
    Filed: January 17, 2020
    Publication date: November 4, 2021
    Inventors: Jianyong Chen, Yunlong Zhou, Guozhi Tang, Chengzhe Wu, Leilei Zhao, Lingling Jiao, Binghua Sheng, Shaomeng Wang, Chao-Yie Yang, Hao Chen, Wenliang Hu, Yu Jing
  • FUSED 1,4-OXAZEPINES AND RELATED ANALOGS AS BET BROMODOMAIN INHIBITORS
    Publication number: 20210188870
    Abstract: The present disclosure provides fused 1,4-oxazepines and related analogs represented by Formula (I) and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R1, R2a, R2b, R3a, R3b, R4, R5, A, and Y are as defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula (I) to treat a condition or disorder responsive to inhibition of BET bromodomains such as cancer.
    Type: Application
    Filed: February 15, 2017
    Publication date: June 24, 2021
    Inventors: Shaomeng WANG, Bing ZHOU, Yang HU, Chao-Yie YANG, Chong QIN
  • 5,6-DIHYDRO-1 1H-INDOLO{2,3-B}QUINOLIN- 11-ONE COMPOUNDS AS ALK INHIBITORS
    Publication number: 20210087188
    Abstract: The present disclosure provides compounds represented by Formula (I) and the pharmaceutically acceptable salts and solvates thereof, wherein R1a, R1b, R2a, R2b, R3, R4, R5, R6, R7, R8, E, Z, and are as defined as set forth in the specification. The present disclosure also provides compounds of Formula (I) for use to treat a condition or disorder responsive to inhibition of ALK such as cancer.
    Type: Application
    Filed: March 21, 2019
    Publication date: March 25, 2021
    Applicant: The Regents oof the University of Michigan
    Inventors: Jianyong CHEN, Liu LIU, Xuyuan DONG, Chao-Yie YANG, Donna McEACHERN, Shaomeng WANG, Yunlong ZHOU, Yu JING
  • MONOFUNCTIONAL INTERMEDIATES FOR LIGAND-DEPENDENT TARGET PROTEIN DEGRADATION
    Publication number: 20210002289
    Abstract: The present disclosure provides compounds represented by Formula I: and the salts or solvates thereof, wherein X, L, Y, and B are as defined in the specification. Compounds having Formula I are immunomodulators and/or monofunctional synthetic intermediates that can be used to prepare small-molecule drug conjugates.
    Type: Application
    Filed: August 31, 2020
    Publication date: January 7, 2021
    Inventors: Yangbing Li, Angelo Aguilar, Bing Zhou, Jiantao Hu, Fuming Xu, Chong Qin, Yang Hu, Weiguo Xiang, Rohan Rej, Jiuling Yang, Xin Han, Longchuan Bai, Chao-Yie Yang
  • 5,6-dihydro-11H-indolo[2,3-B]quinolin-11-ones as alk inhibitors
    Patent number: 10781208
    Abstract: The present disclosure provides compounds represented by Formula (I), and the pharmaceutically acceptable salts and solvates thereof wherein R1a, R1b, R2a, R2b, R3, R4, R5, R6, R7, E and (B) are as defined as set forth in the specification. The present disclosure also provides compounds of Formula (I) for use to treat a condition or disorder responsive to inhibition of ALK such as cancer.
    Type: Grant
    Filed: November 17, 2017
    Date of Patent: September 22, 2020
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Jianyong Chen, Liu Liu, Xuyuan Dong, Chao-Yie Yang, Donna McEachern, Shaomeng Wang
  • Monofunctional intermediates for ligand-dependent target protein degradation
    Patent number: 10759808
    Abstract: The present disclosure provides compounds represented by Formula I: and the salts or solvates thereof, wherein X, L, Y, and B are as defined in the specification. Compounds having Formula I are immunomodulators and/or monofunctional synthetic intermediates that can be used to prepare small-molecule drug conjugates.
    Type: Grant
    Filed: April 6, 2017
    Date of Patent: September 1, 2020
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Shaomeng Wang, Yangbing Li, Angelo Aguilar, Bing Zhou, Jiantao Hu, Fuming Xu, Chong Qin, Yang Hu, Weiguo Xiang, Rohan Rej, Jiuling Yang, Xin Han, Longchuan Bai, Chao-Yie Yang
  • PYRROLO[2,3-C]PYRIDINES AND RELATED ANALOGS AS LSD-1 INHIBITORS
    Publication number: 20200157091
    Abstract: The present disclosure provides compounds represented by Formula I and II: and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3, X, W, Y, and Z are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I and II for use to treat a condition or disorder responsive to LSD1 inhibition such as cancer.
    Type: Application
    Filed: May 15, 2018
    Publication date: May 21, 2020
    Inventors: Shaomeng Wang, Dengyou Zhang, Canhui Zheng, Zhuo Chen, Liu Liu, Liyue Huang, Chao-Yie Yang
  • BET protein degraders
    Patent number: 10633386
    Abstract: The present disclosure provides compounds represented by Formula I: and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein B, R1, R5, Q1, Q?, L, X, Y, and Z are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I for use to treat a condition or disorder responsive to degradation of BET bromodomains such as cancer.
    Type: Grant
    Filed: April 6, 2017
    Date of Patent: April 28, 2020
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Shaomeng Wang, Bing Zhou, Fuming Xu, Jiantao Hu, Longchuan Bai, Chao-Yie Yang
  • 5,6-DIHYDRO-11H-INDOLO[2,3-B]QUINOLIN-11-ONES AS ALK INHIBITORS
    Publication number: 20190315741
    Abstract: The present disclosure provides compounds represented by Formula (I), and the pharmaceutically acceptable salts and solvates thereof wherein R1a, R1b, R2a, R2b, R3, R4, R5, R6, R7, E and (B) are as defined as set forth in the specification. The present disclosure also provides compounds of Formula (I) for use to treat a condition or disorder responsive to inhibition of ALK such as cancer.
    Type: Application
    Filed: November 17, 2017
    Publication date: October 17, 2019
    Inventors: Jianyong Chen, Liu Liu, Xuyuan Dong, Chao-Yie Yang, Donna McEachern, Shaomeng Wang